4AB.F - AbbVie Inc.

Frankfurt - Frankfurt Delayed Price. Currency in EUR
89.63
+0.51 (+0.57%)
At close: 3:46PM CEST
Stock chart is not supported by your current browser
Previous Close89.12
Open89.47
Bid89.91 x 60000
Ask90.10 x 60000
Day's Range88.93 - 89.78
52 Week Range57.79 - 100.00
Volume234
Avg. Volume459
Market Cap143.035B
Beta1.24
PE Ratio (TTM)22.54
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield3.11 (3.59%)
Ex-Dividend Date2018-04-12
1y Target EstN/A
  • Top Analyst Reports for Procter & Gamble, AbbVie, McDonald's & PepsiCo
    Zacks10 hours ago

    Top Analyst Reports for Procter & Gamble, AbbVie, McDonald's & PepsiCo

    Top Analyst Reports for Procter & Gamble, AbbVie, McDonald's & PepsiCo

  • 5 Things AbbVie Investors Need to Know
    Motley Fool4 days ago

    5 Things AbbVie Investors Need to Know

    AbbVie's top executives answer tough questions about the company's products and pipeline.

  • Trump’s Attempt to Shame Drugmakers Shows Medicare Costs Soaring
    Bloomberg6 days ago

    Trump’s Attempt to Shame Drugmakers Shows Medicare Costs Soaring

    The U.S spent 60 percent more on drugs for Medicare patients in 2016 than it did in four years earlier, according to newly released federal data, countering pharmaceutical industry arguments that prescription medicine represents only a small and stable portion of health-care costs. Unit costs for AbbVie Inc.’s Humira, a blockbuster rheumatoid arthritis drug, rose at an average pace of 18 percent a year during the same period, according to the figures released Tuesday by the Trump administration. The government disclosed the information as part of an updated dashboard that includes information on annual drug-price increases for several federal programs, including Medicare, for the elderly, and Medicaid, which covers the poor.

  • 3 Top Healthcare Stocks to Buy in May
    Motley Fool7 days ago

    3 Top Healthcare Stocks to Buy in May

    Looking for a few quality healthcare stock to add to your portfolio today? Start your search with these three gems.

  • 3 Dividend Stocks for In-the-Know Investors
    Motley Fool11 days ago

    3 Dividend Stocks for In-the-Know Investors

    Uniti Group, AbbVie Inc, and American Tower are three strong dividend plays that could help you generate wealth for years to come.

  • Pharma Stock Roundup: Mixed Q1 for MRK, PFE, FDA Nod for Kymriah's 2nd Indication
    Zacks17 days ago

    Pharma Stock Roundup: Mixed Q1 for MRK, PFE, FDA Nod for Kymriah's 2nd Indication

    Earnings are in focus this week with Pfizer (PFE) and Merck (MRK) delivering mixed Q1 numbers. Novartis gains FDA approval for the second indication of its CAR-T therapy, Kymriah.

  • Did Gilead Sciences Make a Big Mistake?
    Motley Fool18 days ago

    Did Gilead Sciences Make a Big Mistake?

    First-quarter results call into question the biopharmaceutical giant's choice to shift its R&D focus away from hepatitis C.

  • Zacks Small Cap Research18 days ago

    NBIX: Strong INGREZZA® Sales Continue in 1Q18; Expanding Sales Team for Future Growth

    By David Bautz, PhD NASDAQ:NBIX INGREZZA® Launch Continues to go Well On April 30, 2018, Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced financial results for the first quarter of 2018 and provided ...

  • MarketWatch18 days ago

    Drugmakers eye a new threat to sales but say it hasn’t affected them — yet

    The most expansive look at the issue this earnings season came from AbbVie Inc. (ABBV) Chief Executive Richard Gonzalez, who spoke at length about the new policies on the company’s first-quarter call last Thursday. The new programs, called co-pay accumulators, prevent patients from using drugmaker coupons to reduce their out-of-pocket costs. Read: Drug companies are beginning to wake up to this new risk factor and Like using that drug coupon?

  • Better Buy: Johnson & Johnson (JNJ) vs. AbbVie (ABBV)
    Motley Fool20 days ago

    Better Buy: Johnson & Johnson (JNJ) vs. AbbVie (ABBV)

    These two big pharma stocks have a lot in common. But only one is the better choice right now.

  • Gilead Sciences' First-Quarter Twist: Weak HIV Sales
    Motley Fool20 days ago

    Gilead Sciences' First-Quarter Twist: Weak HIV Sales

    Continued HCV sales declines for the big biotech were expected, but not anemic growth for its HIV franchise.

  • Associated Press20 days ago

    Seagate, Pfizer and Cummins skid while AbbVie jumps

    Stocks that moved substantially or traded heavily Tuesday: Tapestry Inc., down $6.31 to $47.46 The company's Kate Spade and Stuart Weitzman brands had a weak first quarter. AbbVie Inc., up $5.52 to $102.07 ...

  • Why Nutrisystem, Tenet Healthcare, and AbbVie Jumped Today
    Motley Fool20 days ago

    Why Nutrisystem, Tenet Healthcare, and AbbVie Jumped Today

    Find out which of these companies got some help from earnings season.

  • AbbVie's First Quarter: Can We Quit Worrying About Humira Now?
    Motley Fool23 days ago

    AbbVie's First Quarter: Can We Quit Worrying About Humira Now?

    It looks like the fortress AbbVie Inc.'s lead drug built will be able to stand on its own soon.

  • How AbbVie 'Crushed It' On Hepatitis C As Fellow Drugmaker Bristol Dips
    Investor's Business Daily25 days ago

    How AbbVie 'Crushed It' On Hepatitis C As Fellow Drugmaker Bristol Dips

    AbbVie's hepatitis C franchise "crushed it" in the first quarter, an analyst said Thursday as it and fellow drugmaker Bristol-Myers reported strong profit.

  • A Look At The Intrinsic Value Of AbbVie Inc (NYSE:ABBV)
    Simply Wall St.25 days ago

    A Look At The Intrinsic Value Of AbbVie Inc (NYSE:ABBV)

    How far off is AbbVie Inc (NYSE:ABBV) from its intrinsic value? Using the most recent financial data, I am going to take a look at whether the stock is fairlyRead More...

  • AbbVie (ABBV) Q1 Earnings Beat, 2018 View Up, Stock Gains
    Zacks25 days ago

    AbbVie (ABBV) Q1 Earnings Beat, 2018 View Up, Stock Gains

    AbbVie's (ABBV) Q1 earnings top estimates with revenues marginally beating the same. Sales of the company's lead marketed drug, Humira, also rise year over year.

  • AbbVie Inc Stock Up on Strong Earnings, Guidance Update
    InvestorPlace25 days ago

    AbbVie Inc Stock Up on Strong Earnings, Guidance Update

    This is an increase over its earnings per share of $1.28 from the same time last year. It also beat out Wall Street’s earnings per share estimate of $1.79 for the quarter and was good news for ABBV stock. AbbVie Inc’s net income reported in the first quarter of the year was $2.78 billion.

  • Forbes25 days ago

    Sales Of AbbVie's Hepatitis C Drugs Soar

    Sales AbbVie's drugs for hepatitis C were $919 million in the first quarter of 2018, 60% above the consensus forecasts of Wall Street analysts, helping to boost the company's earnings to $2.8 billion on sales of $7.9 billion, up 33% and 21% from last year.

  • Barrons.com25 days ago

    Drug Makers: A Dose of Robust Earnings

    With earnings season in full swing, pharma stocks got a boost today from AbbVie (ABBV), and Alexion Pharmaceuticals (ALXN), although Bristol-Myers Squibb (BMY) has given up its early gains. AbbVie said ...

  • AbbVie (ABBV) Tops Q1 Earnings and Revenues, View Up
    Zacks25 days ago

    AbbVie (ABBV) Tops Q1 Earnings and Revenues, View Up

    AbbVie's (ABBV) first-quarter 2018 earnings surpassed estimates with revenues marginally beating the same. Sales of its lead marketed drug Humira also increased compared to year ago figure.

  • Associated Press26 days ago

    AbbVie: 1Q Earnings Snapshot

    On a per-share basis, the North Chicago, Illinois-based company said it had net income of $1.74. Earnings, adjusted for one-time gains and costs, came to $1.87 per share. The results beat Wall Street expectations. ...

  • MarketWatch26 days ago

    AbbVie shares rise 3% on Q1 profit, revenue beats and $7.5 billion share buyback

    AbbVie Inc. shares rose nearly 3% in premarket trade Thursday after the company reported first-quarter profit and revenue beats and announced plans to buy back up to $7.5 billion in shares. Adjusted earnings-per-share were $1.87, compared with the FactSet consensus of $1.79. Revenue rose to $7.93 billion from $6.54 billion, compared with the FactSet consensus of $7.60 billion.